Quick Takeaways Why It Matters? CosACTHen gives Dechra a differentiated diagnostic anchor in canine endocrinology and should strengthen its existing Cushing’s/Addison’s franchise built around Vetoryl. As the first and only FDA‑approved cosyntropin spec...
Quick Takeaways: Why It Matters? Relocating the HQ to Boston embeds Dechra in a top-tier life sciences cluster, improving access to R&D talent, BD opportunities, and capital for innovation-driven growth. The shift also signals a stronger strategic emphasis on...
Quick Takeaways: Why It Matters? The VOHC seal gives Vetradent Dental Wipes strong clinical credibility, making vets more likely to recommend them as a trusted home-care option. By adding another VOHC-approved product, Dechra deepens its positionin...
Dechra Secures FDA Approval for Zygolide (Pergolide) in Equine Pituitary Pars Intermedia Dysfunction
Quick Takeaways: Why It Matters? Zygolide gives vets and owners a lower-cost, FDA-approved alternative for managing PPID, which should improve treatment uptake in senior horses. The focus on flexible dosing and palatability makes long-term therapy more practical in th...
